Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6% – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares traded down 14.6% during mid-day trading on Monday . The company traded as low as C$1.24 and last traded at C$1.29. 551,069 shares changed hands during mid-day trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Price Performance

The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59. The company has a market capitalization of C$133.00 million, a P/E ratio of -3.24 and a beta of 1.31. The company has a 50 day moving average price of C$1.49 and a 200 day moving average price of C$1.64.

Cardiol Therapeutics (TSE:CRDL) last released its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. On average, equities analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.